Post-Mass Drug Administration Transmission Assessment Survey for Elimination of Lymphatic Filariasis in La Ciénaga, Dominican Republic.
Identifieur interne : 000B61 ( PubMed/Corpus ); précédent : 000B60; suivant : 000B62Post-Mass Drug Administration Transmission Assessment Survey for Elimination of Lymphatic Filariasis in La Ciénaga, Dominican Republic.
Auteurs : Gregory S. Noland ; Stephen Blount ; Manuel GonzalezSource :
- The American journal of tropical medicine and hygiene [ 1476-1645 ] ; 2015.
English descriptors
- KwdEn :
- Albendazole (therapeutic use), Child, Child, Preschool, Diethylcarbamazine (therapeutic use), Disease Eradication (methods), Dominican Republic (epidemiology), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (prevention & control), Female, Filaricides (therapeutic use), Health Surveys, Humans, Immunochromatography, Male.
- MESH :
- chemical , therapeutic use : Albendazole, Diethylcarbamazine, Filaricides.
- geographic , epidemiology : Dominican Republic.
- drug therapy : Elephantiasis, Filarial.
- epidemiology : Elephantiasis, Filarial.
- methods : Disease Eradication.
- prevention & control : Elephantiasis, Filarial.
- Child, Child, Preschool, Female, Health Surveys, Humans, Immunochromatography, Male.
Abstract
The Dominican Republic is one of four remaining countries in the Americas with lymphatic filariasis (LF). Annual mass drug administration (MDA) with albendazole and diethylcarbamazine was conducted in La Ciénaga, an impoverished urban barrio in Santo Domingo, from 2004 to 2006. Eight years after the last MDA, a transmission assessment survey (TAS) was conducted in November-December 2014 to determine if LF transmission remains absent. Of 815 first and second grade primary school students (mean age: 6.51 years; range 5-9) tested by immunochromatographic test (ICT), zero (0.0%) were positive. This is below the TAS critical cutoff of nine, indicating that the area "passed" TAS and that transmission remains interrupted in La Ciénaga. Importantly, this also provides evidence that three rounds of effective (> 65% coverage) MDA, likely aided by environmental improvements and periodic school-based albendazole monotherapy MDA, achieved interruption of LF transmission from a relatively low-transmission setting.
DOI: 10.4269/ajtmh.15-0204
PubMed: 26503279
Links to Exploration step
pubmed:26503279Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Post-Mass Drug Administration Transmission Assessment Survey for Elimination of Lymphatic Filariasis in La Ciénaga, Dominican Republic.</title><author><name sortKey="Noland, Gregory S" sort="Noland, Gregory S" uniqKey="Noland G" first="Gregory S" last="Noland">Gregory S. Noland</name><affiliation><nlm:affiliation>The Carter Center, Atlanta, Georgia; Centro de Control de Enfermedades Tropicales, Santo Domingo, Dominican Republic gregory.noland@cartercenter.org.</nlm:affiliation></affiliation></author><author><name sortKey="Blount, Stephen" sort="Blount, Stephen" uniqKey="Blount S" first="Stephen" last="Blount">Stephen Blount</name><affiliation><nlm:affiliation>The Carter Center, Atlanta, Georgia; Centro de Control de Enfermedades Tropicales, Santo Domingo, Dominican Republic.</nlm:affiliation></affiliation></author><author><name sortKey="Gonzalez, Manuel" sort="Gonzalez, Manuel" uniqKey="Gonzalez M" first="Manuel" last="Gonzalez">Manuel Gonzalez</name><affiliation><nlm:affiliation>The Carter Center, Atlanta, Georgia; Centro de Control de Enfermedades Tropicales, Santo Domingo, Dominican Republic.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26503279</idno><idno type="pmid">26503279</idno><idno type="doi">10.4269/ajtmh.15-0204</idno><idno type="wicri:Area/PubMed/Corpus">000B61</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B61</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Post-Mass Drug Administration Transmission Assessment Survey for Elimination of Lymphatic Filariasis in La Ciénaga, Dominican Republic.</title><author><name sortKey="Noland, Gregory S" sort="Noland, Gregory S" uniqKey="Noland G" first="Gregory S" last="Noland">Gregory S. Noland</name><affiliation><nlm:affiliation>The Carter Center, Atlanta, Georgia; Centro de Control de Enfermedades Tropicales, Santo Domingo, Dominican Republic gregory.noland@cartercenter.org.</nlm:affiliation></affiliation></author><author><name sortKey="Blount, Stephen" sort="Blount, Stephen" uniqKey="Blount S" first="Stephen" last="Blount">Stephen Blount</name><affiliation><nlm:affiliation>The Carter Center, Atlanta, Georgia; Centro de Control de Enfermedades Tropicales, Santo Domingo, Dominican Republic.</nlm:affiliation></affiliation></author><author><name sortKey="Gonzalez, Manuel" sort="Gonzalez, Manuel" uniqKey="Gonzalez M" first="Manuel" last="Gonzalez">Manuel Gonzalez</name><affiliation><nlm:affiliation>The Carter Center, Atlanta, Georgia; Centro de Control de Enfermedades Tropicales, Santo Domingo, Dominican Republic.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The American journal of tropical medicine and hygiene</title><idno type="eISSN">1476-1645</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (therapeutic use)</term><term>Child</term><term>Child, Preschool</term><term>Diethylcarbamazine (therapeutic use)</term><term>Disease Eradication (methods)</term><term>Dominican Republic (epidemiology)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Female</term><term>Filaricides (therapeutic use)</term><term>Health Surveys</term><term>Humans</term><term>Immunochromatography</term><term>Male</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Dominican Republic</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Disease Eradication</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Health Surveys</term><term>Humans</term><term>Immunochromatography</term><term>Male</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Dominican Republic is one of four remaining countries in the Americas with lymphatic filariasis (LF). Annual mass drug administration (MDA) with albendazole and diethylcarbamazine was conducted in La Ciénaga, an impoverished urban barrio in Santo Domingo, from 2004 to 2006. Eight years after the last MDA, a transmission assessment survey (TAS) was conducted in November-December 2014 to determine if LF transmission remains absent. Of 815 first and second grade primary school students (mean age: 6.51 years; range 5-9) tested by immunochromatographic test (ICT), zero (0.0%) were positive. This is below the TAS critical cutoff of nine, indicating that the area "passed" TAS and that transmission remains interrupted in La Ciénaga. Importantly, this also provides evidence that three rounds of effective (> 65% coverage) MDA, likely aided by environmental improvements and periodic school-based albendazole monotherapy MDA, achieved interruption of LF transmission from a relatively low-transmission setting.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26503279</PMID><DateCreated><Year>2015</Year><Month>12</Month><Day>15</Day></DateCreated><DateCompleted><Year>2016</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-1645</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The American journal of tropical medicine and hygiene</Title><ISOAbbreviation>Am. J. Trop. Med. Hyg.</ISOAbbreviation></Journal><ArticleTitle>Post-Mass Drug Administration Transmission Assessment Survey for Elimination of Lymphatic Filariasis in La Ciénaga, Dominican Republic.</ArticleTitle><Pagination><MedlinePgn>1292-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4269/ajtmh.15-0204</ELocationID><Abstract><AbstractText>The Dominican Republic is one of four remaining countries in the Americas with lymphatic filariasis (LF). Annual mass drug administration (MDA) with albendazole and diethylcarbamazine was conducted in La Ciénaga, an impoverished urban barrio in Santo Domingo, from 2004 to 2006. Eight years after the last MDA, a transmission assessment survey (TAS) was conducted in November-December 2014 to determine if LF transmission remains absent. Of 815 first and second grade primary school students (mean age: 6.51 years; range 5-9) tested by immunochromatographic test (ICT), zero (0.0%) were positive. This is below the TAS critical cutoff of nine, indicating that the area "passed" TAS and that transmission remains interrupted in La Ciénaga. Importantly, this also provides evidence that three rounds of effective (> 65% coverage) MDA, likely aided by environmental improvements and periodic school-based albendazole monotherapy MDA, achieved interruption of LF transmission from a relatively low-transmission setting.</AbstractText><CopyrightInformation>© The American Society of Tropical Medicine and Hygiene.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Noland</LastName><ForeName>Gregory S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>The Carter Center, Atlanta, Georgia; Centro de Control de Enfermedades Tropicales, Santo Domingo, Dominican Republic gregory.noland@cartercenter.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blount</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Carter Center, Atlanta, Georgia; Centro de Control de Enfermedades Tropicales, Santo Domingo, Dominican Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Carter Center, Atlanta, Georgia; Centro de Control de Enfermedades Tropicales, Santo Domingo, Dominican Republic.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Trop Med Hyg</MedlineTA><NlmUniqueID>0370507</NlmUniqueID><ISSNLinking>0002-9637</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005369">Filaricides</NameOfSubstance></Chemical><Chemical><RegistryNumber>F4216019LN</RegistryNumber><NameOfSubstance UI="D015766">Albendazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Trop Med Hyg. 2015 Dec;93(6):1128-9</RefSource><PMID Version="1">26503272</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2005 Sep;10(9):818-25</RefSource><PMID Version="1">16135187</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2014 Nov;8(11):e3319</RefSource><PMID Version="1">25412180</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Wkly Epidemiol Rec. 2013 Feb 15;88(7):75-80</RefSource><PMID Version="1">23540049</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Trop. 2011 Sep;120 Suppl 1:S33-8</RefSource><PMID Version="1">20933491</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 1987 Jul;37(1):111-4</RefSource><PMID Version="1">3300389</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2014 Jul 17;8(7):e2915</RefSource><PMID Version="1">25032697</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 2015 May;92(5):959-66</RefSource><PMID Version="1">25758650</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2003 Nov 1;188(9):1371-81</RefSource><PMID Version="1">14593597</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Filaria J. 2003 Nov 6;2(1):15</RefSource><PMID Version="1">14613509</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Patient Educ Couns. 2007 Nov;68(3):279-86</RefSource><PMID Version="1">17707609</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Parasitol. 1987 Aug;73(4):839-40</RefSource><PMID Version="1">3305853</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2004 Apr;4(4):223-34</RefSource><PMID Version="1">15050941</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lymphat Res Biol. 2013 Sep;11(3):144-8</RefSource><PMID Version="1">24044755</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="Y">Disease Eradication</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004293" MajorTopicYN="N" Type="Geographic">Dominican Republic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059665" MajorTopicYN="N">Immunochromatography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>03</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>07</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26503279</ArticleId><ArticleId IdType="pii">ajtmh.15-0204</ArticleId><ArticleId IdType="doi">10.4269/ajtmh.15-0204</ArticleId><ArticleId IdType="pmc">PMC4674248</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B61 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000B61 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26503279
|texte= Post-Mass Drug Administration Transmission Assessment Survey for Elimination of Lymphatic Filariasis in La Ciénaga, Dominican Republic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26503279" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |